June 9th 2023
Review top news and interview highlights from the week ending June 9, 2023.
Novel Bispecific T Cell Engager BI 764532 Shows Manageable Tolerability in DLL3+ SCLC and Neuroendocrine CarcinomaJune 5th 2023
Additionally, promising efficacy signals were reported—namely response rates and disease control rates—in the phase 1 clinical trial (NCT04429087) data that were presented at the 2023 ASCO Annual Meeting.
European Application Submitted for Cilta-cel in Relapsed and Lenalidomide-Refractory MyelomaMay 30th 2023
The Type II variation application for ciltacabtagene autoleucel in adult patients with relapsed and lenalidomide-refractory multiple myeloma is supported by data from the phase 3 CARTITUDE-4 trial.
Bringing HLA-A*02-directed CAR T to Solid Tumor Care With the EVEREST-1 TrialMay 22nd 2023
Diane M. Simeone, MD, discussed the phase 1/2 EVEREST-1 trial, which seeks to assess the novel CAR T-cell therapy A2B530 in patients with solid tumors—hopefully progressing one-and-done engineered therapies in this population.